Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Klaudia FarkasMariann RutkaTamás FerenciFerenc NagyAnita BálintRenáta BorÁgnes CsontosAnna FábiánKata SzántóZsuzsanna VéghZsuzsanna KürtiPéter L LakatosZoltán SzepesTamás MolnárPublished in: Expert opinion on biological therapy (2017)
This study confirmed the long-term efficacy and safety of CT-P13 therapy in IBD. Response rates at week 54 were similar in CD and UC.